import type { Metadata } from 'next';
import { Breadcrumbs } from '@/components/breadcrumbs';
import { AutoLink } from '@/components/auto-link';
import Link from 'next/link';
import Image from 'next/image';
import {
  Calendar, User, Clock, ShieldAlert, ArrowLeft, ArrowRight,
  FlaskConical, Zap, CheckCircle2, XCircle, Shield, TrendingDown,
  Brain, Activity, AlertCircle, Info
} from 'lucide-react';
import { ShareBar } from '@/components/share-bar';
import { CiteThisPage } from '@/components/cite-page';
import { AuthorBio } from '@/components/author-bio';
import { SHORT_DISCLAIMER } from '@/data/constants';
import { LibraryCallout } from '@/components/library-callout';
import { getAuthorSlug } from '@/data/authors';
import { BlogVendorCallout } from '@/components/blog-vendor-callout';

/* ─── META ─────────────────────────────────────────────────────────── */

const POST_TITLE = 'Tesamorelin: What Sets It Apart from Every Other Growth Hormone Peptide';
const POST_DESC =
  'A deep-dive comparison of Tesamorelin vs Sermorelin, CJC-1295, Ipamorelin, and MK-677. Covers mechanism, visceral fat specificity, clinical evidence, and who Tesamorelin is actually best suited for.';
const AUTHOR = 'PeptideX Editorial';
const DATE_PUB = '2026-04-13';
const DATE_MOD = '2026-04-13';
const SLUG = 'tesamorelin-growth-hormone-peptide-comparison';
const CANONICAL = `https://peptidex.app/blog/${SLUG}`;

export const metadata: Metadata = {
  title: `${POST_TITLE} | PeptiDex Blog`,
  description: POST_DESC,
  keywords: [
    'Tesamorelin peptide', 'Tesamorelin vs Sermorelin', 'Tesamorelin vs CJC-1295',
    'Tesamorelin vs Ipamorelin', 'growth hormone peptides 2026', 'visceral fat reduction',
    'GH peptide comparison', 'GHRH analogs', 'peptide therapy for fat loss',
    'Tesamorelin benefits', 'Tesamorelin anti-aging',
  ],
  alternates: { canonical: CANONICAL },
  openGraph: {
    title: POST_TITLE,
    description: POST_DESC,
    url: CANONICAL,
    type: 'article',
    images: [{ url: 'https://peptidex.app/images/blog/tesamorelin_growth_hormone_comparison.png', width: 1200, height: 630 }],
  },
  twitter: {
    card: 'summary_large_image',
    title: POST_TITLE,
    description: POST_DESC,
    images: ['https://peptidex.app/images/blog/tesamorelin_growth_hormone_comparison.png'],
  },
};

/* ─── SCHEMAS ───────────────────────────────────────────────────────── */

const blogSchema = {
  '@context': 'https://schema.org',
  '@type': 'BlogPosting',
  headline: POST_TITLE,
  description: POST_DESC,
  author: { '@type': 'Organization', name: 'PeptideX Research', url: 'https://peptidex.app' },
  publisher: {
    '@type': 'Organization',
    name: 'PeptideX',
    logo: { '@type': 'ImageObject', url: 'https://peptidex.app/favicon.ico' },
  },
  image: 'https://peptidex.app/images/blog/tesamorelin_growth_hormone_comparison.png',
  datePublished: `${DATE_PUB}T12:00:00Z`,
  dateModified: `${DATE_MOD}T12:00:00Z`,
  mainEntityOfPage: { '@type': 'WebPage', '@id': CANONICAL },
};

const breadcrumbSchema = {
  '@context': 'https://schema.org',
  '@type': 'BreadcrumbList',
  itemListElement: [
    { '@type': 'ListItem', position: 1, name: 'Home', item: 'https://peptidex.app/' },
    { '@type': 'ListItem', position: 2, name: 'Blog', item: 'https://peptidex.app/blog' },
    { '@type': 'ListItem', position: 3, name: 'Tesamorelin Comparison', item: CANONICAL },
  ],
};

const faqSchema = {
  '@context': 'https://schema.org',
  '@type': 'FAQPage',
  mainEntity: [
    {
      '@type': 'Question',
      name: 'Is Tesamorelin FDA approved?',
      acceptedAnswer: {
        '@type': 'Answer',
        text: 'Yes. Tesamorelin (brand name Egrifta) received FDA approval in 2010 for the treatment of excess abdominal fat (lipodystrophy) in HIV-infected patients on antiretroviral therapy. It is the only growth hormone-stimulating peptide with FDA approval.',
      },
    },
    {
      '@type': 'Question',
      name: 'How does Tesamorelin differ from Sermorelin?',
      acceptedAnswer: {
        '@type': 'Answer',
        text: 'Tesamorelin uses the full 44-amino acid GHRH sequence with a stability modification, while Sermorelin uses only the first 29 amino acids. Tesamorelin produces stronger GH and IGF-1 responses, preferentially targets visceral adipose tissue with reductions of 15-20% in clinical trials, and is backed by robust Phase III clinical data. Sermorelin is less expensive and is commonly used for general wellness and GH support.',
      },
    },
    {
      '@type': 'Question',
      name: 'Can Tesamorelin be stacked with Ipamorelin?',
      acceptedAnswer: {
        '@type': 'Answer',
        text: 'Yes — and this is one of the most clinically rational combinations available. Tesamorelin acts via the GHRH pathway while Ipamorelin acts via the ghrelin/GHS-R1a pathway. When combined, Ipamorelin suppresses somatostatin tone while Tesamorelin provides the positive secretory signal, producing synergistic GH pulses that pharmacodynamic studies show can be 2-3x greater than either alone.',
      },
    },
    {
      '@type': 'Question',
      name: 'What is the main advantage of Tesamorelin over CJC-1295?',
      acceptedAnswer: {
        '@type': 'Answer',
        text: "CJC-1295 (with DAC) binds to serum albumin for extended duration, which can cause GHRH receptor desensitization over time — blunting GH pulse amplitude. Tesamorelin's shorter duration of action allows the receptor to resensitize between doses, preserving the pituitary's ability to respond strongly to each administration with physiologically normal GH pulses.",
      },
    },
    {
      '@type': 'Question',
      name: 'Who is Tesamorelin best suited for?',
      acceptedAnswer: {
        '@type': 'Answer',
        text: 'Tesamorelin is best suited for patients with significant visceral fat accumulation, individuals managing metabolic health issues (insulin resistance, NAFLD, cardiovascular risk), those who prioritize FDA-backed clinical evidence, and patients using it as part of a dual-pathway stack with a GHRP like Ipamorelin. It may not be the optimal choice for patients seeking gentle, low-cost GH support or those who prioritize oral convenience.',
      },
    },
  ],
};

/* ─── COMPARISON TABLE DATA ─────────────────────────────────────────── */
type ComparisonRow = {
  label: string;
  tesamorelin: string;
  sermorelin: string;
  cjc1295: string;
  ipamorelin: string;
  mk677: string;
  tesamorelinPos: boolean | null;
};

const COMPARISON: ComparisonRow[] = [
  { label: 'Mechanism', tesamorelin: 'GHRH analog (full 44-AA)', sermorelin: 'GHRH analog (29-AA)', cjc1295: 'GHRH + albumin (DAC)', ipamorelin: 'GHRP / ghrelin agonist', mk677: 'Oral ghrelin mimetic', tesamorelinPos: null },
  { label: 'FDA Approved', tesamorelin: 'Yes (Egrifta)', sermorelin: 'Discontinued (2008)', cjc1295: 'No', ipamorelin: 'No', mk677: 'No', tesamorelinPos: true },
  { label: 'Visceral Fat Reduction', tesamorelin: '15–20% in clinical trials', sermorelin: 'Modest, non-specific', cjc1295: 'Mild body composition', ipamorelin: 'Indirect (via GH)', mk677: 'Minimal/variable', tesamorelinPos: true },
  { label: 'Receptor Desensitization Risk', tesamorelin: 'Low (pulsatile)', sermorelin: 'Low', cjc1295: 'Moderate–High (DAC)', ipamorelin: 'Very Low', mk677: 'Moderate', tesamorelinPos: true },
  { label: 'Cortisol / Prolactin Elevation', tesamorelin: 'None reported', sermorelin: 'None', cjc1295: 'Minimal', ipamorelin: 'None (highly selective)', mk677: 'Minimal', tesamorelinPos: null },
  { label: 'Phase III Clinical Data', tesamorelin: 'Robust (TESOMET trial)', sermorelin: 'Limited', cjc1295: 'Limited', ipamorelin: 'Limited', mk677: 'Moderate', tesamorelinPos: true },
  { label: 'Estimated Monthly Cost', tesamorelin: '$1,000–$3,000', sermorelin: '$200–$500', cjc1295: '$300–$800', ipamorelin: '$150–$400', mk677: '$50–$150', tesamorelinPos: false },
  { label: 'Route of Administration', tesamorelin: 'Subcutaneous injection', sermorelin: 'Subcutaneous injection', cjc1295: 'Subcutaneous injection', ipamorelin: 'Subcutaneous injection', mk677: 'Oral', tesamorelinPos: null },
];

const BEST_FOR_ITEMS = [
  { icon: <TrendingDown className="w-5 h-5 text-amber-400 flex-shrink-0" />, text: 'Patients with significant visceral fat requiring targeted, organ-level reduction' },
  { icon: <Activity className="w-5 h-5 text-amber-400 flex-shrink-0" />, text: 'Individuals managing metabolic health: insulin resistance, cardiovascular risk, or NAFLD' },
  { icon: <Shield className="w-5 h-5 text-amber-400 flex-shrink-0" />, text: 'Patients who want FDA-backed efficacy — not just preclinical or anecdotal evidence' },
  { icon: <Zap className="w-5 h-5 text-amber-400 flex-shrink-0" />, text: 'Those stacking with Ipamorelin for synergistic dual-pathway GH amplification' },
  { icon: <Brain className="w-5 h-5 text-amber-400 flex-shrink-0" />, text: 'Anti-aging and longevity protocols emphasizing physiologically aligned GH stimulation' },
];

/* ─── COMPONENT ─────────────────────────────────────────────────────── */

export default function TesamorelinArticle() {
  return (
    <div className="max-w-4xl mx-auto px-4 py-8 md:py-12 relative space-y-12">
      <script type="application/ld+json" dangerouslySetInnerHTML={{ __html: JSON.stringify(blogSchema) }} />
      <script type="application/ld+json" dangerouslySetInnerHTML={{ __html: JSON.stringify(breadcrumbSchema) }} />
      <script type="application/ld+json" dangerouslySetInnerHTML={{ __html: JSON.stringify(faqSchema) }} />

      {/* Breadcrumbs */}
      <Breadcrumbs items={[
        { name: 'Home', url: 'https://peptidex.app/' },
        { name: 'Blog', url: 'https://peptidex.app/blog' },
        { name: 'Tesamorelin vs GH Peptides' }
      ]} />

      {/* Back */}
      <Link href="/blog" className="inline-flex items-center gap-2 text-sm text-zinc-400 hover:text-white transition-colors mb-8 group">
        <ArrowLeft className="w-4 h-4 group-hover:-translate-x-1 transition-transform" />
        Back to Blog
      </Link>

      {/* ══ HERO IMAGE ══ */}
      <div className="relative w-full h-56 md:h-72 rounded-2xl overflow-hidden border border-zinc-800 mb-4">
        <Image
          src="/images/blog/tesamorelin_growth_hormone_comparison.png"
          alt="A single glowing amber peptide vial on an obsidian surface with molecular diagrams etched around it, representing Tesamorelin"
          fill
          className="object-cover"
          sizes="(max-width: 768px) 100vw, 896px"
          unoptimized
          priority
        />
        <div className="absolute inset-0 bg-gradient-to-t from-zinc-950/70 via-transparent to-transparent" />
      </div>

      {/* ══ DISCLAIMER ══ */}
      <div className="rounded-xl bg-amber-950/25 border border-amber-500/20 p-4">
        <div className="flex items-start gap-2">
          <ShieldAlert className="w-5 h-5 text-amber-500 flex-shrink-0 mt-0.5" />
          <p className="text-sm text-amber-400/80 leading-relaxed font-medium">
            <strong>EDUCATIONAL CONTENT:</strong> {SHORT_DISCLAIMER}
          </p>
        </div>
      </div>

      {/* ══ HEADER ══ */}
      <header className="space-y-6">
        <div className="flex flex-wrap items-center gap-3">
          <span className="px-3 py-1 text-[10px] font-bold uppercase tracking-widest bg-amber-500/15 text-amber-300 rounded-full border border-amber-500/30">
            Growth Hormone
          </span>
          <span className="px-3 py-1 text-[10px] font-bold uppercase tracking-widest bg-violet-500/15 text-violet-300 rounded-full border border-violet-500/30">
            Peptide Therapy
          </span>
          <span className="px-3 py-1 text-[10px] font-bold uppercase tracking-widest bg-emerald-500/15 text-emerald-300 rounded-full border border-emerald-500/30">
            Fat Loss
          </span>
          <span className="px-3 py-1 text-[10px] font-bold uppercase tracking-widest bg-sky-500/15 text-sky-300 rounded-full border border-sky-500/30">
            Longevity
          </span>
        </div>
        <h1 className="text-3xl md:text-4xl lg:text-5xl font-extrabold tracking-tight text-zinc-100 leading-tight">
          Tesamorelin: What Sets It Apart from <span className="text-amber-400">Every Other</span> Growth Hormone Peptide
        </h1>
        <div className="flex flex-wrap items-center gap-4 text-sm text-zinc-400 border-t border-b border-zinc-800/50 py-4">
          <div className="flex items-center gap-2">
            <User className="w-4 h-4 text-amber-400" />
            <Link href={`/about/${getAuthorSlug(AUTHOR)}`} className="font-semibold text-zinc-200 hover:text-amber-400 transition-colors">{AUTHOR}</Link>
          </div>
          <div className="w-1.5 h-1.5 rounded-full bg-zinc-700" />
          <div className="flex items-center gap-2">
            <Calendar className="w-4 h-4 text-zinc-500" />
            <span>April 13, 2026</span>
          </div>
          <div className="w-1.5 h-1.5 rounded-full bg-zinc-700" />
          <div className="flex items-center gap-2">
            <Clock className="w-4 h-4 text-zinc-500" />
            <span>15 min read</span>
          </div>
          <div className="w-1.5 h-1.5 rounded-full bg-zinc-700" />
          <div className="flex items-center gap-2">
            <FlaskConical className="w-4 h-4 text-amber-400" />
            <span className="text-amber-300 font-medium">GH Peptide Analysis</span>
          </div>
        </div>
        <ShareBar title={POST_TITLE} url={CANONICAL} />
      </header>

      {/* ══ MAIN ARTICLE ══ */}
      <AutoLink>
      <article className="prose prose-invert prose-zinc max-w-none prose-headings:font-bold prose-h2:text-2xl prose-h2:text-zinc-200 prose-h2:mt-12 prose-h2:mb-6 prose-h2:pb-2 prose-h2:border-b prose-h2:border-zinc-800 prose-p:text-zinc-300 prose-p:leading-loose prose-a:text-amber-400 prose-a:no-underline hover:prose-a:underline prose-strong:text-zinc-200 prose-ul:text-zinc-300 prose-li:marker:text-amber-500">

        {/* LEAD */}
        <p className="lead text-xl text-zinc-300 font-medium">
          In a crowded field of growth hormone peptides &mdash; Sermorelin, Ipamorelin, CJC-1295, Hexarelin, GHRP-2, MK-677 &mdash; one compound consistently occupies a unique position: <strong>Tesamorelin</strong>. It&apos;s the only growth hormone-stimulating peptide with FDA approval. It&apos;s the only one backed by robust Phase III clinical trial data for visceral fat reduction. And its mechanism, while sharing the same receptor target as other GHRH analogs, produces a pharmacological profile that no other peptide in this class can replicate.
        </p>
        <p>
          If you&apos;re evaluating growth hormone peptides for fat loss, body composition, metabolic health, or anti-aging purposes, understanding how Tesamorelin differentiates itself isn&apos;t just academic &mdash; it&apos;s the difference between choosing the right tool for the job and settling for a less precise one.
        </p>

        <h2 id="what-is-tesamorelin">What Tesamorelin Actually Is</h2>
        <p>
          Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) &mdash; the signaling molecule your body naturally produces to tell the pituitary gland to release growth hormone. Marketed under the brand name <strong>Egrifta</strong>, it received FDA approval in 2010 specifically for treating excess abdominal fat (lipodystrophy) in HIV-infected patients on antiretroviral therapy.
        </p>
        <p>
          Structurally, Tesamorelin is built on the <strong>complete 44-amino acid sequence of human GHRH</strong>. This is a critical distinction. Other popular GHRH analogs, like Sermorelin and CJC-1295, use truncated versions of that sequence — Sermorelin contains only the first 29 amino acids, while CJC-1295 starts from a modified 29-amino acid fragment and adds drug affinity complex (DAC) technology.
        </p>
        <p>
          Tesamorelin&apos;s stability modification is targeted and elegant: a <em>trans-3-hexenoic acid group</em> is attached to the N-terminal tyrosine residue. This small chemical addition blocks the enzyme DPP-IV from rapidly breaking down the peptide, extending its functional half-life without fundamentally altering how it interacts with the GHRH receptor. The result is a compound whose receptor engagement geometry closely mirrors native GHRH &mdash; but lasts long enough to produce a therapeutically meaningful growth hormone pulse.
        </p>

        {/* KEY DIFFERENTIATOR CALLOUT */}
        <div className="not-prose my-8 bg-amber-950/20 border border-amber-500/30 rounded-2xl p-6">
          <div className="flex items-start gap-3">
            <Info className="w-5 h-5 text-amber-400 flex-shrink-0 mt-0.5" />
            <div>
              <p className="text-sm font-bold text-amber-300 mb-1 uppercase tracking-wide">Key Structural Differentiator</p>
              <p className="text-sm text-zinc-300 leading-relaxed">
                Tesamorelin uses the <strong>full 44-amino acid GHRH sequence</strong>. Sermorelin uses 29. CJC-1295 also uses a 29-AA fragment but adds albumin-binding DAC technology. That single structural choice cascades into meaningfully different receptor engagement, GH pulse dynamics, and clinical outcomes.
              </p>
            </div>
          </div>
        </div>

        {/* ══ COMPARISON TABLE ══ */}
        <div className="not-prose my-12 overflow-x-auto rounded-2xl border border-zinc-800 bg-zinc-900/50">
          <p className="text-xs uppercase tracking-widest font-bold text-zinc-500 px-6 pt-5 pb-3">At-a-Glance GH Peptide Comparison</p>
          <table className="w-full text-sm min-w-[700px]">
            <thead>
              <tr className="border-b border-zinc-800">
                <th className="text-left py-3 px-4 text-zinc-400 font-semibold w-40">Factor</th>
                <th className="text-left py-3 px-4 text-amber-300 font-bold">Tesamorelin</th>
                <th className="text-left py-3 px-4 text-zinc-300 font-semibold">Sermorelin</th>
                <th className="text-left py-3 px-4 text-zinc-300 font-semibold">CJC-1295</th>
                <th className="text-left py-3 px-4 text-zinc-300 font-semibold">Ipamorelin</th>
                <th className="text-left py-3 px-4 text-zinc-300 font-semibold">MK-677</th>
              </tr>
            </thead>
            <tbody>
              {COMPARISON.map((row, i) => (
                <tr key={row.label} className={`border-b border-zinc-800/50 ${i % 2 === 0 ? 'bg-zinc-900/30' : ''}`}>
                  <td className="py-3 px-4 text-zinc-400 font-medium text-xs">{row.label}</td>
                  <td className="py-3 px-4">
                    <span className={`text-xs font-semibold ${row.tesamorelinPos === true ? 'text-emerald-400' : row.tesamorelinPos === false ? 'text-rose-400' : 'text-amber-300'}`}>
                      {row.tesamorelin}
                    </span>
                  </td>
                  <td className="py-3 px-4 text-xs text-zinc-400">{row.sermorelin}</td>
                  <td className="py-3 px-4 text-xs text-zinc-400">{row.cjc1295}</td>
                  <td className="py-3 px-4 text-xs text-zinc-400">{row.ipamorelin}</td>
                  <td className="py-3 px-4 text-xs text-zinc-400">{row.mk677}</td>
                </tr>
              ))}
            </tbody>
          </table>
        </div>

        <h2 id="vs-sermorelin">How It Differs from Sermorelin</h2>
        <p>
          Sermorelin is often the first GHRH analog people encounter, primarily because of its accessibility and lower cost. It&apos;s a 29-amino acid fragment of GHRH &mdash; the minimum sequence needed to retain biological activity at the GHRH receptor. It was originally FDA-approved for diagnosing and treating growth hormone deficiency in children, though the commercial product (Geref) was discontinued in 2008 due to manufacturing issues, not safety concerns.
        </p>
        <p>The differences between Tesamorelin and Sermorelin come down to <strong>potency, specificity, and clinical evidence</strong>.</p>

        <div className="not-prose my-8 grid grid-cols-1 md:grid-cols-2 gap-4">
          {[
            { label: 'Potency', icon: <Zap className="w-4 h-4 text-amber-400" />, text: 'Tesamorelin produces a stronger GH response and more pronounced IGF-1 elevation. Clinical research consistently demonstrates more robust GH release and greater effects on body composition.' },
            { label: 'Visceral Fat Specificity', icon: <TrendingDown className="w-4 h-4 text-amber-400" />, text: 'Tesamorelin\'s defining advantage. Clinical trials have demonstrated 15–20% reductions in visceral adipose tissue in 3–4 months. Sermorelin shows some body composition improvements, but the magnitude and specificity simply aren\'t there.' },
            { label: 'Clinical Validation', icon: <Shield className="w-4 h-4 text-amber-400" />, text: 'The TESOMET trial and Phase III studies provide robust peer-reviewed data. More recent research shows a 32% liver fat reduction in NAFLD patients (JCEM). Sermorelin has a solid safety record but lacks this level of targeted validation.' },
            { label: 'Cost', icon: <Activity className="w-4 h-4 text-amber-400" />, text: 'Tesamorelin runs $1,000–$3,000/month at clinics vs. $200–$500 for Sermorelin through compounding pharmacies. For general wellness and gentle GH support, Sermorelin\'s price point often wins. For urgent visceral fat reduction, Tesamorelin\'s cost is justified.' },
          ].map(item => (
            <div key={item.label} className="bg-zinc-900 border border-zinc-800 rounded-xl p-5 hover:border-amber-500/30 transition-colors">
              <div className="flex items-center gap-2 mb-2">
                {item.icon}
                <h4 className="font-bold text-zinc-200 text-sm">{item.label}</h4>
              </div>
              <p className="text-xs text-zinc-400 leading-relaxed">{item.text}</p>
            </div>
          ))}
        </div>

        <h2 id="vs-cjc1295">How It Differs from CJC-1295</h2>
        <p>
          CJC-1295 is another GHRH analog, but its engineering takes a fundamentally different approach. Where Tesamorelin uses a small chemical modification to block enzymatic degradation, CJC-1295 (with DAC) uses drug affinity complex technology that binds the peptide covalently to serum albumin. Albumin has a circulatory half-life of approximately 19 days &mdash; so CJC-1295 extends its duration of action from hours to days.
        </p>
        <p>This sounds like an advantage, but it introduces a significant trade-off.</p>

        <div className="not-prose my-8 bg-rose-950/20 border-l-4 border-rose-500 p-6 rounded-r-xl">
          <h4 className="text-base font-bold text-rose-400 mb-2 flex items-center gap-2">
            <AlertCircle className="w-5 h-5" /> The Receptor Desensitization Trade-Off
          </h4>
          <p className="text-sm text-zinc-300 leading-relaxed">
            The GHRH receptor, like most G protein-coupled receptors, undergoes desensitization with prolonged agonist exposure. CJC-1295&apos;s sustained albumin-bound presence can lead to a <strong>blunted GH secretion pattern over time</strong> &mdash; a flatter, sustained elevation rather than the sharp physiological pulses that optimize GH&apos;s anabolic and fat-metabolizing effects. Tesamorelin&apos;s shorter duration of action preserves receptor sensitivity between doses.
          </p>
        </div>

        <p>
          In practical terms, Tesamorelin produces GH pulses that more closely resemble the body&apos;s natural rhythm. CJC-1295 produces a more sustained, baseline elevation. <strong>Neither is inherently superior</strong> &mdash; the right choice depends entirely on the goal of the protocol.
        </p>

        {/* VENDOR CTA */}
        <div className="not-prose my-10 rounded-2xl bg-gradient-to-br from-amber-900/30 to-zinc-900 border border-amber-500/30 p-6 shadow-xl relative overflow-hidden group">
          <div className="absolute top-0 right-0 w-32 h-32 bg-amber-500/10 blur-[50px] rounded-full pointer-events-none transition-all group-hover:bg-amber-500/20" />
          <h4 className="text-xl font-bold text-zinc-100 mb-2 flex items-center gap-2">
            <Shield className="w-5 h-5 text-amber-400" /> Research Verified Sources
          </h4>
          <p className="text-sm text-zinc-300 mb-6 max-w-lg leading-relaxed">
            Tesamorelin is one of the most precisely compounded peptides on the market. We track COA-verified vendors for GH peptides including Tesamorelin, CJC-1295, and Ipamorelin.
          </p>
          <Link
            href="/vendors"
            rel="nofollow noopener sponsored"
            className="inline-flex items-center justify-center gap-2 px-6 py-3 rounded-xl bg-amber-600 hover:bg-amber-500 text-white font-bold transition-all shadow-lg hover:shadow-amber-500/25"
          >
            View COA-Verified Vendors <ArrowRight className="w-5 h-5" />
          </Link>
        </div>

        <h2 id="vs-ipamorelin">How It Differs from Ipamorelin and Other GHRPs</h2>
        <p>
          This is where the comparison gets most interesting, because <strong>Ipamorelin doesn&apos;t compete with Tesamorelin &mdash; it complements it</strong>.
        </p>
        <p>
          Ipamorelin belongs to an entirely different class: growth hormone-releasing peptides (GHRPs) that act on ghrelin receptors (GHS-R1a) rather than GHRH receptors. While both classes stimulate the pituitary to release growth hormone, they do it through <strong>separate signaling pathways</strong>.
        </p>

        <div className="not-prose my-8 bg-emerald-950/20 border border-emerald-500/25 rounded-2xl p-6">
          <h4 className="text-sm font-bold text-emerald-400 mb-3 uppercase tracking-wide flex items-center gap-2">
            <CheckCircle2 className="w-4 h-4" /> The Synergy Opportunity
          </h4>
          <p className="text-sm text-zinc-300 leading-relaxed">
            Pairing <strong>Tesamorelin (GHRH pathway)</strong> with <strong>Ipamorelin (ghrelin pathway)</strong> creates a dual-pathway synergy. The GHRP reduces somatostatin tone — the inhibitory brake on GH release — while Tesamorelin provides the accelerating signal. Pharmacodynamic data shows this combination can produce <strong>2–3× greater GH pulses</strong> than either compound alone. Experienced clinicians don&apos;t view them as competitors. They view them as the two halves of an optimized protocol.
          </p>
        </div>

        <p>
          Other GHRPs like Hexarelin and GHRP-2 also stimulate the ghrelin pathway but come with more side effects. Hexarelin is the most potent GHRP available but loses effectiveness over time due to receptor desensitization and can elevate cortisol and prolactin. GHRP-2 sits between Ipamorelin and Hexarelin in potency and side effect profile.
        </p>

        <h2 id="vs-mk677">How It Differs from MK-677</h2>
        <p>
          MK-677 (Ibutamoren) shows up in nearly every GH peptide comparison, even though it technically isn&apos;t a peptide &mdash; it&apos;s a non-peptide ghrelin receptor agonist taken <em>orally</em>. Its primary advantage is convenience: no injections required. But that convenience comes with trade-offs.
        </p>

        <div className="not-prose my-6 grid grid-cols-1 md:grid-cols-2 gap-4">
          <div className="bg-zinc-900/60 border border-zinc-800 rounded-xl p-5">
            <div className="flex items-center gap-2 mb-3 text-emerald-400">
              <CheckCircle2 className="w-4 h-4 flex-shrink-0" />
              <p className="text-sm font-bold text-zinc-200">MK-677 Advantages</p>
            </div>
            <ul className="space-y-1.5">
              {['Oral — no injections', 'Low cost ($50–$150/mo)', 'Consistent GH/IGF-1 elevation'].map(t => (
                <li key={t} className="text-xs text-zinc-400 flex items-start gap-2"><span className="text-emerald-500 mt-0.5">+</span>{t}</li>
              ))}
            </ul>
          </div>
          <div className="bg-zinc-900/60 border border-zinc-800 rounded-xl p-5">
            <div className="flex items-center gap-2 mb-3 text-rose-400">
              <XCircle className="w-4 h-4 flex-shrink-0" />
              <p className="text-sm font-bold text-zinc-200">MK-677 Trade-offs</p>
            </div>
            <ul className="space-y-1.5">
              {['Significant appetite spikes', 'Water retention / "puffy" look', 'Potential blood glucose effects', 'Less selective ghrelin signaling'].map(t => (
                <li key={t} className="text-xs text-zinc-400 flex items-start gap-2"><span className="text-rose-500 mt-0.5">-</span>{t}</li>
              ))}
            </ul>
          </div>
        </div>

        <p>
          Tesamorelin operates through an entirely different pathway (GHRH vs. ghrelin) and produces a more targeted metabolic response. Where MK-677 raises GH and IGF-1 through continuous ghrelin signaling &mdash; leading to the appetite and water retention effects &mdash; Tesamorelin&apos;s action is more focused on stimulating natural GH pulsatility without the ghrelin-related side effects.
        </p>

        <h2 id="expanding-research">Tesamorelin&apos;s Expanding Research Profile</h2>
        <p>Beyond its established role in visceral fat reduction, Tesamorelin is gaining attention in several emerging research areas:</p>

        <div className="not-prose my-8 space-y-4">
          {[
            { icon: <Brain className="w-5 h-5 text-violet-400" />, title: 'Cognitive Health', body: 'Studies are examining Tesamorelin\'s potential effects in conditions involving GH/IGF-1 axis dysfunction and cognitive decline. The connection between growth hormone signaling and brain health is an active area of investigation, and Tesamorelin\'s ability to meaningfully elevate IGF-1 makes it a compound of interest.' },
            { icon: <Activity className="w-5 h-5 text-emerald-400" />, title: 'Liver Fat and NAFLD', body: 'Research showing a 32% reduction in liver fat among non-HIV patients with non-alcoholic fatty liver disease has opened the door to potential applications beyond its original FDA indication. As metabolic disease continues rising globally, a peptide that targets both visceral and hepatic fat has obvious clinical relevance.' },
            { icon: <Shield className="w-5 h-5 text-amber-400" />, title: 'Anti-Aging and Longevity', body: 'Tesamorelin\'s potent effects on body composition, combined with its ability to stimulate natural GH production without suppressing the body\'s own feedback mechanisms, make it an increasingly popular longevity protocol option. Unlike exogenous HGH, Tesamorelin works within the body\'s own endocrine system.' },
          ].map(item => (
            <div key={item.title} className="flex items-start gap-4 p-5 bg-zinc-900 border border-zinc-800 rounded-xl hover:border-amber-500/30 transition-colors">
              <div className="mt-0.5 w-9 h-9 rounded-full bg-zinc-800 border border-zinc-700/50 flex items-center justify-center flex-shrink-0">
                {item.icon}
              </div>
              <div>
                <h4 className="text-zinc-100 font-bold text-sm mb-1">{item.title}</h4>
                <p className="text-xs text-zinc-400 leading-relaxed">{item.body}</p>
              </div>
            </div>
          ))}
        </div>

        <h2 id="best-for">Who Is Tesamorelin Best For?</h2>
        <p>Given its specific strengths and trade-offs, Tesamorelin is best suited for the following profiles:</p>

        <div className="not-prose my-8 bg-zinc-900/40 border border-zinc-800 rounded-2xl p-6">
          <div className="space-y-4">
            {BEST_FOR_ITEMS.map((item, i) => (
              <div key={i} className="flex items-start gap-3">
                {item.icon}
                <p className="text-sm text-zinc-300 leading-relaxed">{item.text}</p>
              </div>
            ))}
          </div>
          <div className="mt-6 pt-5 border-t border-zinc-800">
            <p className="text-xs text-zinc-500 leading-relaxed">
              <strong className="text-zinc-400">May not be the right fit for:</strong> patients seeking gentle, long-term GH support at a lower price point (where Sermorelin is often the better choice), or those who prioritize oral convenience over targeted efficacy (where MK-677 fills the niche).
            </p>
          </div>
        </div>

        <h2 id="bottom-line">The Bottom Line</h2>
        <p>
          Tesamorelin doesn&apos;t just occupy a spot on the growth hormone peptide spectrum &mdash; it occupies a <strong>unique position that no other compound in this class can claim</strong>. Its FDA approval, its visceral fat specificity, its full-length GHRH structure, and its expanding research profile collectively set it apart from every alternative.
        </p>
        <p>
          In a field where many compounds offer overlapping benefits and interchangeable value propositions, Tesamorelin stands alone in what it does best: targeted, clinically validated visceral fat reduction through potent, physiologically aligned growth hormone stimulation.
        </p>
        <p>
          The growth hormone peptide you choose should match your specific goals, your health profile, and your budget. But if visceral fat is the target, the clinical evidence points in one direction.
        </p>

      </article>
      </AutoLink>

      {/* ══ LIBRARY CALLOUT ══ */}
      <LibraryCallout currentSlug={SLUG} peptides={[
        { name: 'CJC-1295', slug: 'cjc-1295' },
        { name: 'IPAMORELIN', slug: 'ipamorelin' },
        { name: 'BPC-157', slug: 'bpc-157' },
        { name: 'TB-500', slug: 'tb-500' },
      ]} />

      {/* ══ CITE ══ */}
      <div className="mb-12">
        <CiteThisPage title={POST_TITLE} url={CANONICAL} />
      </div>

      {/* ══ FAQ SECTION ══ */}
      <section className="border-t border-zinc-800 pt-12 mt-12 pb-8">
        <h2 className="text-2xl font-bold text-zinc-100 text-center mb-8">Frequently Asked Questions</h2>
        <div className="max-w-3xl mx-auto space-y-4">
          {faqSchema.mainEntity.map((q, idx) => (
            <div key={idx} className="bg-zinc-900/60 border border-zinc-800 rounded-xl p-6">
              <h3 className="text-md font-bold text-zinc-200 mb-3">{q.name}</h3>
              <p className="text-zinc-400 text-sm leading-relaxed">{q.acceptedAnswer.text}</p>
            </div>
          ))}
        </div>
      </section>

      {/* ══ FOOTER ELEMENTS ══ */}
      <ShareBar title={POST_TITLE} url={CANONICAL} />
      <BlogVendorCallout />
      <AuthorBio name={AUTHOR} />

      {/* ══ DISCLAIMER ══ */}
      <div className="mt-16 p-6 rounded-2xl bg-zinc-900 border border-zinc-800 flex flex-col gap-2">
        <p className="text-xs text-zinc-500 uppercase tracking-widest font-bold">Disclaimer</p>
        <p className="text-sm text-zinc-400 leading-relaxed italic">
          This article is for informational purposes only and does not constitute medical advice. Tesamorelin requires a physician&apos;s prescription. Consult with a licensed healthcare provider to determine if Tesamorelin is appropriate for your individual health goals and medical history.
        </p>
      </div>

      {/* ══ RELATED TOPICS ══ */}
      <div className="flex flex-wrap gap-2 pt-4">
        {[
          'Tesamorelin peptide', 'Tesamorelin vs Sermorelin', 'Tesamorelin vs CJC-1295',
          'Tesamorelin vs Ipamorelin', 'growth hormone peptides 2026', 'visceral fat reduction',
          'GH peptide comparison', 'GHRH analogs', 'peptide therapy for fat loss',
          'Tesamorelin benefits', 'Tesamorelin anti-aging',
        ].map(tag => (
          <span key={tag} className="px-3 py-1.5 text-[10px] font-semibold uppercase tracking-wider bg-zinc-800/60 text-zinc-400 rounded-full border border-zinc-700/50">
            {tag}
          </span>
        ))}
      </div>
    </div>
  );
}
